Hyperdynamic circulation in cirrhosis: a novel gutsy central neuronal mechanism Akash ShuklaAditya Kale Editorial 15 April 2023 Pages: 517 - 518
MAFLD and chronic kidney disease: two sides of the same coin? Ziyan PanSaleh A. AlqahtaniMohammed Eslam Editorial 17 April 2023 Pages: 519 - 521
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver Darrell H. G. CrawfordGrant A. RammJohn K. Olynyk Guidelines Open access 17 April 2023 Pages: 522 - 541
Evolution of risk prediction models for post-operative mortality in patients with cirrhosis Eric KaloJacob GeorgeGolo Ahlenstiel Consensus Open access 27 March 2023 Pages: 542 - 545
Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN) Jacob GeorgeGeorge LauMohammed Eslam Point-of-View Open access 20 April 2023 Pages: 546 - 549
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry Te-Sheng ChangChung-Feng HuangMing-Lung Yu Original Article 27 March 2023 Pages: 550 - 561
The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population Shuntaro ObiMiho KandaMasao Omata Original Article 22 February 2023 Pages: 562 - 572
Fibro-Scope V1.0.1: an artificial intelligence/neural network system for staging of nonalcoholic steatohepatitis Kanji YamaguchiToshihide ShimaTakeshi Okanoue Original Article 21 December 2022 Pages: 573 - 583
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence Phillip E. MeltonM. A. BurtonR. C. Huang Original Article Open access 03 February 2023 Pages: 584 - 594
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants Shen ChenJuan PangXu Chen Original Article 21 February 2023 Pages: 595 - 605
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study Asahiro MorishitaKyoko OuraTsutomu Masaki Original Article Open access 30 December 2022 Pages: 606 - 614
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis Hong FanZhenqiu LiuTiejun Zhang Original Article 31 March 2023 Pages: 615 - 625
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu KangYu Rim LeeJung Gil Park Original Article 17 April 2023 Pages: 626 - 635
Intracellular labile iron is a key regulator of hepcidin expression and iron metabolism Yanmeng LiQin OuyangAnjian Xu Original Article 13 December 2022 Pages: 636 - 647
DENND3 p.L708V activating variant is involved in the pathogenesis of hereditary hemochromatosis via the RAB12/TFR2 signaling pathway Yanmeng LiAnjian XuJian Huang Original Article 02 February 2023 Pages: 648 - 661
AARC score determines outcomes in patients with alcohol-associated hepatitis: a multinational study Rakhi MaiwallSamba Siva Rao PasupuletiShiv Kumar Sarin Original Article 26 December 2022 Pages: 662 - 675
Genetic landscape and immune mechanism of monocytes associated with the progression of acute-on-chronic liver failure Jia YaoTian LiuJun Xu Original Article Open access 10 January 2023 Pages: 676 - 688
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats Hongqun LiuNoura AlhassanSamuel S. Lee Original Article 01 February 2023 Pages: 689 - 697
Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis Berivan GurbuzNurdan GuldikenPavel Strnad Original Article Open access 18 January 2023 Pages: 698 - 708
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients Xu YangBowen ChenHaitao Zhao Original Article Open access 08 February 2023 Pages: 709 - 719
The differences in post-liver transplant outcomes of patients with autoimmune hepatitis who present with overlapping autoimmune liver diseases David Uihwan LeeReid PonderNathalie Helen Urrunaga Original Article 27 December 2022 Pages: 720 - 734
Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma Ryo ItoKoji MiyanishiJunji Kato Original Article 04 February 2023 Pages: 735 - 744
Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study Tushar PrabhakarKanica KaushalShiv Kumar Sarin Original Article 20 March 2023 Pages: 745 - 752
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma Yujing XinXinyuan ZhangXiao Li Original Article 10 April 2023 Pages: 753 - 764
Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study Renguo GuanJie MeiRongping Guo Letter to the Editor 07 January 2023 Pages: 765 - 769
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion Avinash TiwariRiffat Abdul AzizRiddhima Tripathi Letter to the Editor 08 February 2023 Pages: 770 - 772